Partners
Created in 1981 as a joint venture between Nestle and L'Oreal, Galderma is one of the leading dermatology companies in the world according to recent IMS D-Class survey. With a worldwide presence in 65 countries Galderma has over 900 sales representatives dedicated to dermatology. Galderma is a fully integrated specialty pharmaceutical company with a global sales and marketing structure and worldwide product development capability. Galderma provides innovative therapeutic skincare solutions to meet the needs of dermatology patients and physicians. The company is committed to improving the health of skin with an extensive line of products that treat a range of skincare conditions including: acne, rosacea, fungal nail infections, psoriasis, seborrheic dermatitis, pigmentary disorders, non-melanoma skin cancer and photo-damage.
With a new research and development lab in Sophia Antipolis (France) Galderma has one of the largest R&D facilities dedicated to dermatology. Galderma is also poised to continue making significant impact on dermatology treatments with the introduction of exciting technology and products on the horizon. More information is available online at www.galderma.com
Endo Pharmaceuticals Holdings Inc. is a fully integrated specialty pharmaceutical company with market leadership in pain management products. Through its Endo Pharmaceuticals Inc. subsidiary, the company researches, develops, produces and markets a broad product offering of both branded and generic pharmaceuticals, meeting the needs of healthcare professionals and consumers alike. More information, is available online at www.endo.com.
EUSA Pharma is a rapidly growing transatlantic specialty pharmaceutical company focused on inlicensing, developing and marketing late-stage oncology, pain control and critical care products. The company currently has 5 products on the market, including Erwinase® and Kidrolase® for the treatment of acute lymphoblastic leukemia, and Rapydan®, a rapid-onset anaesthetic patch for which EUSA Pharma expects to receive Europe-wide approval later this year.
Supported by leading life science investors, Essex Woodlands, 3i, Goldman Sachs, Advent Venture Partners, SV Life Sciences, NeoMed and NovaQuest, EUSA Pharma has raised over $225 million and completed three significant acquisitions since its founding in May 2006. Maintaining its focus on oncology, pain control and critical care, the company is currently seeking partners for the non-core development programs it gained as part of its recent acquisitions, in Alzheimer's disease, multiple sclerosis, anti-psychosis and inflammatory diseases. More information is available online at www.eusapharma.com